Physician profile
Eric L Reding
NPI 1255386827
$1,651.18
in general payments reported to CMS, 2019-2025
13 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $11.73 · 2021: $111 · 2022: $445 · 2023: $204 · 2024: $639 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.29 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $257.06 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $249.48 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $220.01 | 2021-2024 | Tremfya |
| Abbvie INC. | $218.51 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $199.98 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $173.92 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $135.81 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $83.90 | 2020-2025 | |
| Amgen INC. | $53.39 | 2022-2024 | Otezla |
| Organon LLC | $17.53 | 2025 | Vtama |
| Lilly USA, LLC | $15.83 | 2022 | |
| Janssen Scientific Affairs, LLC | $13.58 | 2019 | |
| Mayne Pharma Commercial LLC | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Reding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.